Emerging drugs for the treatment of scleroderma: a review of recent phase 2 and 3 trials - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Expert Opinion on Emerging Drugs Année : 2020

Emerging drugs for the treatment of scleroderma: a review of recent phase 2 and 3 trials

Résumé

INTRODUCTION: Systemic sclerosis (SSc) has the highest case-specific mortality of all connective tissue diseases. Its underlying disease mechanism affects several organs and remains incompletely understood. Ongoing work clarifying its etiopathogenesis is helping to develop targeted therapy. AREAS COVERED: Several clinical trials have evaluated the safety and efficacy of agents targeting different mechanisms of this disease. This review article reviews those mechanisms and surveys four key recent phase II or III clinical trials that are contributing to the landscape of SSc therapy. The reported trials primarily focus on patients with systemic sclerosis in the early phase of disease. EXPERT OPINION: Traditional therapies for SSc center on immunosuppressive and cytotoxic agents. A new cadre of therapies is borne from improved understandings of SSc pathobiology and target the inflammatory-fibrotic pathways. Scleroderma trials have entered the initial phase of personalized medicine, recognizing molecular subsets that will improve upon cohort enrichment and maximize the measurable benefit of future therapies.

Dates et versions

hal-03003288 , version 1 (13-11-2020)

Identifiants

Citer

David Roofeh, Alain Lescoat, Dinesh Khanna. Emerging drugs for the treatment of scleroderma: a review of recent phase 2 and 3 trials. Expert Opinion on Emerging Drugs, 2020, 25 (4), pp.455-466. ⟨10.1080/14728214.2020.1836156⟩. ⟨hal-03003288⟩
16 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More